Meet with our product experts in one-on-one virtual sessions
Set Up a Meeting
Acalabrutinib
Anti-Cáncer / Oncologico
Acetato De Abiraterona
Anti-Cáncer / Oncologico
Ácido Zoledrónico
Anti-Cáncer / Oncologico
Adagrasib
Anti-Cáncer / Oncologico
Bortezomib
Anti-Cáncer / Oncologico
Cabazitaxel
Anti-Cáncer / Oncologico
Cabozantinib HCl
Anti-Cáncer / Oncologico
Cabozantinib S-Malate
Anti-Cáncer / Oncologico
Carfilzomib
Anti-Cáncer / Oncologico
Clorhidrato De Bendamustina
Anti-Cáncer / Oncologico
Darolutamide
Anti-Cáncer / Oncologico
Dasatinib
Anti-Cáncer / Oncologico
Deucravacitinib
Anti-Cáncer / Oncologico
Enzalutamida
Anti-Cáncer / Oncologico
Fosaprepitante
Anti-Cáncer / Oncologico
Fruquintinib
Anti-Cáncer / Oncologico
Gemcitabine Hydrochloride
Anti-Cáncer / Oncologico
Granisteron
Anti-Cáncer / Oncologico
Lenalidomida
Anti-Cáncer / Oncologico
Lenvatinib Mesylate (Form-C)
Anti-Cáncer / Oncologico
Lenvatinib Mesylate (MIBK Solvate)
Anti-Cáncer / Oncologico
Lomustina
Anti-Cáncer / Oncologico
Mesilato De Eribulina
Anti-Cáncer / Oncologico
Midostaurina
Anti-Cáncer / Oncologico
Nilotinib Clorhidrato
Anti-Cáncer / Oncologico
Niraparib Tosylate
Anti-Cáncer / Oncologico
Olaparib (Form A)
Anti-Cáncer / Oncologico
Palbociclib
Anti-Cáncer / Oncologico
Pazopanib
Anti-Cáncer / Oncologico
Pemetrexed Disodium (Heptahidrato)
Anti-Cáncer / Oncologico
Pirtobrutinib
Anti-Cáncer / Oncologico
Pomalidomida
Anti-Cáncer / Oncologico
Relugolix
Anti-Cáncer / Oncologico
Ripretinib
Anti-Cáncer / Oncologico
Ritlecitinib
Anti-Cáncer / Oncologico
Ruxolitinib Phosphate
Anti-Cáncer / Oncologico
Tucatinib
Anti-Cáncer / Oncologico
Venetoclax
Anti-Cáncer / Oncologico
Oncology/Anticancer API Products Manufacturer and Supplier
Dr. Reddy's is a global leader in developing APIs in the Oncology/Anti-cancer therapy area, with deep technical and scientific knowledge established over decades. With a strong presence across six continents and 39 countries, we are a partner of choice for supplying APIs to leading oncology formulators globally.
As one of the largest generic pharmaceutical manufacturers in the world, we have established a niche in generic oncology APIs and partner of choice for supplying APIs to leading oncology formulators globally.
Our various classes of API under anti-cancer portfolio are as follows:
Kinase Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
BCL-2 Inhibitor
*Countries referred in the above graphic denotes DMF filing geographies
Androgen Receptor (AR) Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
Folate Analog Metabolic Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
Nucleoside Metabolic Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
Microtubule Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
Proteasome Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
Thalidomide Analogue
*Countries referred in the above graphic denotes DMF filing geographies
CYP17 Inhibitor
*Countries referred in the above graphic denotes DMF filing geographies
Bifunctional Mechlorethamine
*Countries referred in the above graphic denotes DMF filing geographies
Nucleoside Metabolic Inhibitor
*Countries referred in the above graphic denotes DMF filing geographies
Alkylating Agent
*Countries referred in the above graphic denotes DMF filing geographies
Poly (ADP-ribose) Polymerase
*Countries referred in the above graphic denotes DMF filing geographies
CXCR4 Chemokine Receptor
*Countries referred in the above graphic denotes DMF filing geographies
GnRH Receptor Antagonist
*Countries referred in the above graphic denotes DMF filing geographies
Chemical Permeation Enhancer
*Countries referred in the above graphic denotes DMF filing geographies
Dr. Reddys Portfolio of Anti-cancer APIs
We manufacture our Anti-cancer APIs at cGMP API manufacturing facilities which are successfully inspected by international regulatory authorities such as the USFDA, EMEA, ANVISA, PMDA, and Health Canada.
Our team of process experts draws on their integrated understanding of IP, process development (API and formulation), and API manufacturing to ensure that by design, the process is lean, free from potential genotoxic impurities, and scalable to manufacture for early market entries. This is of particular importance to select the optimal synthesis route in the context of the IP situation. Other aspects are the solid-state forms and particle characteristics that are critical in formulation development.
We have incorporated sensitive and rigorous analytical methods to control the impurities at a specified level and extensively studied the flow properties, crystal size/shape, and morphology in accordance with future requirements. In addition, our APIs have been designed to address customized PSD requirements through size reduction and crystallization techniques, resulting in a high probability of successful formulation development.
USPs of our Anti-cancer APIs
- QbD approach for an efficient process & high-quality output
- Availability of APIs in various forms.
- cGMP API manufacturing facility - Successfully inspected by international regulatory authorities.
- GTIs & impurities are controlled below the TTC limit & ICH limits, respectively.
- Formulation dossier filed across all major markets.
- Regulatory filing available across the globe.
- Completely backward integrated on the Key starting materials to ensure uninterrupted supplies.
- Adequate capacity to meet the global demands.
- KSM suppliers with timely deliveries and adherence to stringent specifications.
- Process safety management guidelines are implemented to enable a sustainable product supply.
- IP-Compliant API that meets regulatory requirements.
Renuncia
Ninguna información en este sitio web, incluyendo cualquier referencia a cualquier producto o servicio, constituye una oferta de venta ni se interpretará como tal. Los productos protegidos por patentes válidas no se ofrecen ni suministran para uso comercial. Sin embargo, en ciertos casos, a discreción exclusiva de Dr. Reddy's y sujeto a los requisitos legales locales, las cantidades de investigación de dichos productos pueden ofrecerse para fines de presentaciones regulatorias según la Sección 107A de la Ley de Patentes de la India (exención de Bolar), donde existan dichas exenciones regulatorias. Los compradores deben realizar su propia evaluación del producto o servicio, incluyendo el escenario de patentes en sus respectivos mercados, y serán responsables de todas las responsabilidades relacionadas con las patentes. Dr. Reddy's renuncia a todas las garantías, expresas o implícitas, incluyendo, entre otras, las garantías de comerciabilidad, idoneidad para un propósito particular y no infracción.
Let’s talk API sourcing live at
Tackle sourcing bottlenecks and compliance hurdles